XBIO
Closed
Xenetic Biosciences Inc
3.93
0.00 (0.00%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 3.93
Day's Range: 3.73 - 4.01
Send
sign up or login to leave a comment!
When Written:
0.463
Xenetic Biosciences Inc. is a clinical-stage biopharmaceutical company that specializes in the development of targeted therapeutics for the treatment of rare diseases and oncology. The company's lead product candidate, XBIO-101, is a potential treatment for progesterone receptor-negative endometrial cancer. Xenetic Biosciences also has a proprietary drug delivery technology platform called PolyXen, which allows for the development of next-generation biologic drugs with improved pharmacokinetics and reduced immunogenicity. The company is based in Lexington, Massachusetts, and was founded in 2011.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
0.463
Xenetic Biosciences Inc. is a clinical-stage biopharmaceutical company that focuses on developing next-generation biologic drugs and novel oncology therapeutics. The company's proprietary drug development platform called PolyXen enables the production of protein and peptide drugs with improved pharmacokinetic and pharmacodynamic properties.
The company's lead product candidate, XBIO-101, is a tumor-targeted immuno-oncology agent that is being developed for the treatment of pancreatic cancer and other solid tumors. Xenetic Biosciences is also developing a pipeline of other drug candidates, including a hemophilia A therapy and a treatment for sickle cell disease.
Xenetic Biosciences Inc. was founded in 2011 and is headquartered in Framingham, Massachusetts. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "XBIO".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead product candidate, XBIO-101, is a tumor-targeted immuno-oncology agent that is being developed for the treatment of pancreatic cancer and other solid tumors. Xenetic Biosciences is also developing a pipeline of other drug candidates, including a hemophilia A therapy and a treatment for sickle cell disease.
Xenetic Biosciences Inc. was founded in 2011 and is headquartered in Framingham, Massachusetts. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "XBIO".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!